NCT04316624View on ClinicalTrials.gov

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 29, 2019

Primary Completion Date

February 8, 2023

Study Completion Date

February 8, 2023

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

C-CAR066

Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT04316624 - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy | Biotech Hunter | Biotech Hunter